News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NicOx SA (COX.PA) - Major Progress In 2013 In Building An International Ophthalmic Company



1/6/2014 9:25:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOPHIA ANTIPOLIS, France, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX) today provides a summary of its progress in 2013. In line with the strategy announced in 2012, Nicox is making rapid progress in building an international ophthalmic company with a range of ophthalmic diagnostics and eye care products marketed in the United States and in Europe. During this important evolution year, the Company launched Sjö, a novel diagnostic test, in the United States, acquired Eupharmed in Italy and saw its lead R&D asset latanoprostene bunod enter Phase 3 for glaucoma. The Company intends to continue expanding its portfolio through in-licensing, distribution and acquisition agreements.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
NicOx SA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES